AGX9904

AGX9904 is a generic oral liquid drug candidate developed by Agenix Pharmaceuticals, a New Jersey-based pharmaceutical company and contract development and manufacturing organization (CDMO). The candidate is part of a portfolio of niche generic oral liquid dosage forms (including AGX9901 through AGX9905) intended for oral administration. While the specific active pharmaceutical ingredient (API) and target therapeutic indication have not been publicly disclosed by the developer, the program was positioned for an Abbreviated New Drug Application (ANDA) filing, with a target completion date in the third quarter of 2021. Agenix Pharmaceuticals focuses on the development and manufacturing of generic oral liquid products, providing an alternative to traditional solid oral dosage forms.